Gastric cancer screening: a systematic review and meta-analysis
- PMID: 35531944
- DOI: 10.1080/00365521.2022.2068966
Gastric cancer screening: a systematic review and meta-analysis
Abstract
Background and aims: Gastric cancer (GC) screening is recommended in high-risk populations, although screening methods and intervals vary. In intermediate-risk populations, screening through esophagogastroduodenoscopy (EGD) may be considered depending on local resources. The aim of this study was to compare GC screening methods regarding effect on mortality, diagnostic yield and adherence.
Methods: Systematic review and meta-analysis including studies evaluating population-based GC screening. Search was conducted in three online databases (MEDLINE, Scopus and clinicaltrials.gov), along with manual search.
Results: Forty-four studies were included. Studies in upper gastrointestinal series (UGIS) demonstrated that GC screening was associated with significantly lower GC mortality rates (OR 0.63, 95% CI 0.55 - 0.73). Benefits on mortality were also found in EGD and serum pepsinogen (PG) studies. EGD was associated with significantly higher GC (0.55%, 95% CI 0.39 - 0.75%) and early-GC (EGC) detection rates (0.48%, 95% CI 0.34 - 0.65%) when compared to UGIS (GC 0.19%, 95% CI 0.10 - 0.31%; EGC 0.08%, 95% CI 0.04 - 0.13%) and PG (GC 0.10%, 95% CI 0.05 - 0.16%; EGC 0.10%, 95% CI 0.04 - 0.19%). Non-invasive methods tended to higher adherence rates when compared to EGD. Regardless of the screening method, individualized recruitment performed better.
Discussion: Screening positively impacted GC mortality rates. EGD was associated with higher diagnostic yield, while UGIS and PG tended to higher adherence rates. Screening uptake was predominantly impacted by recruitment strategies independently of the adopted method.
Keywords: Gastric cancer; cancer screening; early detection of cancer; gastrointestinal endoscopy; preventive medicine.
Similar articles
-
Effect of gastric cancer screening on long-term survival of gastric cancer patients: results of Korean national cancer screening program.J Gastroenterol. 2022 Jul;57(7):464-475. doi: 10.1007/s00535-022-01878-4. Epub 2022 May 14. J Gastroenterol. 2022. PMID: 35568752
-
Performance of different gastric cancer screening methods in Korea: a population-based study.PLoS One. 2012;7(11):e50041. doi: 10.1371/journal.pone.0050041. Epub 2012 Nov 29. PLoS One. 2012. PMID: 23209638 Free PMC article.
-
Trends in the Performance of the Korean National Cancer Screening Program for Gastric Cancer from 2007 to 2016.Cancer Res Treat. 2022 Jul;54(3):842-849. doi: 10.4143/crt.2021.482. Epub 2021 Sep 30. Cancer Res Treat. 2022. PMID: 34607395 Free PMC article.
-
Identifying high-risk individuals for gastric cancer surveillance from western and eastern perspectives: Lessons to learn and possibility to develop an integrated approach for daily practice.World J Gastroenterol. 2019 Jul 21;25(27):3546-3562. doi: 10.3748/wjg.v25.i27.3546. World J Gastroenterol. 2019. PMID: 31367156 Free PMC article. Review.
-
Esophagogastroduodenoscopy Quality Improvement and the Role of Topical Antiperistaltic Agents: A Systematic Review and Meta-Analysis.Cureus. 2024 Nov 17;16(11):e73855. doi: 10.7759/cureus.73855. eCollection 2024 Nov. Cureus. 2024. PMID: 39559431 Free PMC article. Review.
Cited by
-
Population effectiveness of endoscopy screening for mortality reduction in gastric cancer.DEN Open. 2023 Sep 19;4(1):e296. doi: 10.1002/deo2.296. eCollection 2024 Apr. DEN Open. 2023. PMID: 37731836 Free PMC article.
-
Endoscopic Imaging for the Diagnosis of Neoplastic and Pre-Neoplastic Conditions of the Stomach.Cancers (Basel). 2023 Apr 25;15(9):2445. doi: 10.3390/cancers15092445. Cancers (Basel). 2023. PMID: 37173912 Free PMC article. Review.
-
Current Status of Gastric Cancer Screening and Future Perspectives.DEN Open. 2025 May 26;6(1):e70148. doi: 10.1002/deo2.70148. eCollection 2026 Apr. DEN Open. 2025. PMID: 40433232 Free PMC article. Review.
-
Radiographic and endoscopic screening to reduce gastric cancer mortality: a systematic review and meta-analysis.Lancet Reg Health West Pac. 2023 Mar 11;35:100741. doi: 10.1016/j.lanwpc.2023.100741. eCollection 2023 Jun. Lancet Reg Health West Pac. 2023. PMID: 37424675 Free PMC article.
-
Saliva-derived transcriptomic signature for gastric cancer detection using machine learning and leveraging publicly available datasets.Sci Rep. 2025 May 27;15(1):18491. doi: 10.1038/s41598-025-96864-0. Sci Rep. 2025. PMID: 40425785 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous